Dr. Evan Manolis Appointed Chairman of the Board for Acrongenomics, Inc.

GENEVA--(Business Wire)--
Acrongenomics Inc. (OTCBB: AGNM) today announces that Dr. Evan
Manolis is appointed Chairman of its Board of Directors effective
immediately.

Dr. Manolis has been a board member of Acrongenomics since 2006.
He received his B.Sc. from University of Illinois at Chicago and his
Medical Degree from Southern Illinois University Medical School in
1991. He completed his general surgery residency at the Medical
College in Ohio in 1996, his plastic surgery residency in 1998 and his
microsurgery fellowship in 1999. Dr. Manolis currently practices
reconstructive surgery in the Chicago Illinois area.

The Company also announces the immediate appointment of Dr.
Kailash C. Sharma as a consultant to the Company and as a member of
the Scientific Advisory Board. Dr. Sharma has over 25 years of
clinical experience in the areas of Pulmonary and Internal medicine.
He is a medical graduate from the University of Delhi, India, 1981,
received his fellowships to the Royal College of Physicians in Ireland
and the UK in 1985 and is ABIM certified in the USA for Internal
Medicine, Pulmonary Diseases and Critical Care Medicine with 13
publications to his credit. Dr. Sharma is currently a practicing
physician in the areas of Pulmonary/critical care in the Chicago area.

Furthermore, the Board of Directors of Acrongenomics accepts with
immediate effect the resignation of Dr. Dimitri Goundis from the
position of the Company CEO, which he held since September 2007. Dr.
Goundis leaves Acrongenomics to pursue other business opportunities,
but will continue to act as a consultant to Acrongenomics on business
and management issues.

Lastly, the Company announces that it is moving its offices from
Geneva to London, to be closer to its business interests. The
Company's new address is Fairfax House, 15 Fulwood Place, London, WC1V
6AY United Kingdom.

About Acrongenomics:

Acrongenomics Inc. is a publicly traded company that focuses on
investing in and commercializing novel technology platforms concerning
the Life Sciences sector. Acrongenomics brings novel and realistic
concepts to market by transforming scientific innovations into
tangible, consumer-orientated applications. The company has its
headquarters in Geneva, Switzerland.

Important Information About Forward-Looking Statements

All statements in this news release that are other than statements
of historical facts are forward-looking statements which contain our
current expectations about our future results. Forward-looking
statements involve numerous risks and uncertainties. We have attempted
to identify any forward-looking statements by using words such as
"anticipates", "believes", "could", "expects", "intends", "may",
"should" and other similar expressions. Although we believe that the
expectations reflected in all of our forward looking statements are
reasonable, we can give no assurance that such expectations will prove
to be correct. A number of factors may affect our future results and
may cause those results to differ materially from those indicated in
any forward-looking statements made by us or on our behalf. Such
factors include our limited operating history; our need for
significant capital to finance internal growth as well as strategic
acquisitions; our ability to attract and retain key employees and
strategic partners; our ability to achieve and maintain profitability;
fluctuations in the trading price and volume of our stock; competition
from other providers of similar products and services; and other
unanticipated future events and conditions. For further information
concerning risks and uncertainties that may affect our future results,
please review the disclosures contained in our latest filings with the
SEC, including our most recent annual report on Form 10-KSB, and
subsequent quarterly reports on Form 10-QSB. Other than as required by
federal securities laws, we undertake no obligation to publicly update
or revise any of our forward-looking statements, whether as a result
of changed circumstances, new information, future events, or for any
other reason occurring after the date of this news release.

Acrongenomics Inc.
Platon Tzouvalis, President,
+41 227165300

Copyright Business Wire 2008